Dawnrays Pharmaceutical Holdings Ltd (2348)

Currency in HKD
1.380
-0.040(-2.82%)
Delayed Data·

2348 Financial Summary

Key Ratios

P/E Ratio2.9
Price/Book0.49
Debt / Equity1.04%
Return on Equity18.19%
Dividend Yield6.69%
EBITDA302.83M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.38%
Dividend Yield
6.69%
Industry Median 2.37%
Annualised payout
0.10
Paid unevenly
5-Years Growth
+2.69%
Growth Streak

Earnings

Latest Release
Apr 23, 2025
EPS / Forecast
0.05 / --
Revenue / Forecast
482.86M / --
EPS Revisions
Last 90 days

FAQ

What were Dawnrays Pharma's earnings for the latest quarter?

The Dawnrays Pharma EPS (TTM) is 0.38. Dawnrays Pharma reported sales of 482.86, net income of 71.89, and EPS of 0.05 for the latest quarter.

What was Dawnrays Pharma's net income for the latest quarter?

Dawnrays Pharma's net income for the latest quarter was 71.89.

How did Dawnrays Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 577.45 in the previous quarter to 482.86 in the latest quarter, and net income moved from 493.05 to 71.89 compared to the previous quarter.

What is Dawnrays Pharma's net profit margin on a TTM basis?

Dawnrays Pharma's trailing twelve months (TTM) net profit margin is 53.28%.

How does Dawnrays Pharma's debt to equity ratio compare to industry standards?

Dawnrays Pharma's total debt-to-equity ratio is 1.04%.

What is Dawnrays Pharma's return on investment on a TTM basis?

Dawnrays Pharma's trailing twelve months (TTM) return on investment (ROI) is 18.19%.

Did Dawnrays Pharma gain or lose cash last quarter?

In the latest quarter, Dawnrays Pharma's net change in cash was 68.35 million.

What were Dawnrays Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Dawnrays Pharma reported total assets of 4,009.28 million and total liabilities of 554.60 million.

How has Dawnrays Pharma's total revenue grown this year?

Dawnrays Pharma's total revenue was 577.45 in the previous quarter and 482.86 in the latest quarter.

What is Dawnrays Pharma's gross margin on a TTM basis?

Dawnrays Pharma's trailing twelve months (TTM) gross margin is 50.18%.

What was Dawnrays Pharma's revenue per share for the latest quarter?

Dawnrays Pharma's revenue per share for the latest quarter was 5.54.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.